https://orcid.org/0000-0001-7743-741X
Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Matteo Rosellini, Elisa Tassinari, Andrea Marchetti, Valentina Tateo, Giacomo Nuvola, Alessandro Rizzo, Francesco Massari & Veronica Mollica. (2023) An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma. Expert Opinion on Drug Safety 22:4, pages 279-291.
Read now
Read now
Junyan Wu, Jianxiang Huang, Jianhong Zhu, Zhichao He, Mengting Chen, Siyuan Gao, Dan Liang, Xiaoxia Yu & Chengyu Lu. (2023) Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance study. Expert Opinion on Drug Safety 22:3, pages 231-235.
Read now
Read now
Arman Alimohammadi, Harun Fajkovic, Mesut Remzi, Shahrokh Shariat & Manuela Schmidinger. (2022) Recent pharmacological approaches for the treatment of renal cell carcinoma. Expert Review of Clinical Pharmacology 15:2, pages 187-195.
Read now
Read now
Matteo Santoni, Alessandro Rizzo, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Benedetta Fragomeno, Nicola Battelli & Francesco Massari. (2022) Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. Expert Review of Pharmacoeconomics & Outcomes Research 22:1, pages 45-51.
Read now
Read now
Alessandro Rizzo, Matteo Santoni, Veronica Mollica, Francesco Logullo, Matteo Rosellini, Andrea Marchetti, Luca Faloppi, Nicola Battelli & Francesco Massari. (2021) Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opinion on Drug Metabolism & Toxicology 17:12, pages 1455-1466.
Read now
Read now
Alessandro Rizzo, Veronica Mollica, Matteo Santoni & Francesco Massari. (2021) Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis. Expert Review of Gastroenterology & Hepatology 15:10, pages 1225-1232.
Read now
Read now
Alessandro Rizzo, Sara Merler, Giulia Sorgentoni, Marco Oderda, Veronica Mollica, Gennaro Gadaleta-Caldarola, Matteo Santoni & Francesco Massari. (2021) Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. Expert Opinion on Drug Metabolism & Toxicology 17:10, pages 1237-1243.
Read now
Read now
Alessia Cimadamore, Alessandro Rizzo, Veronica Mollica, Francesco Massari, Antonio Lopez-Beltran, Marina Scarpelli, Liang Cheng, Matteo Santoni & Rodolfo Montironi. (2021) An update on immunotherapy in uro-oncology. Expert Review of Precision Medicine and Drug Development 6:4, pages 229-233.
Read now
Read now
Alessandro Rizzo & Giovanni Brandi. (2021) Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Review of Gastroenterology & Hepatology 15:5, pages 547-554.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2021) Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opinion on Investigational Drugs 30:4, pages 343-350.
Read now
Read now
Articles from other publishers (49)
Anjali Bhatt, Alyson Haslam & Vinay Prasad. (2023) The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review. Journal of Cancer Research and Clinical Oncology 149:10, pages 7355-7362.
Crossref
Crossref
Gaetano Aurilio, Giovanni Mauri, Duccio Rossi, Paolo Della Vigna, Guido Bonomo, Gianluca Maria Varano, Daniele Maiettini, Maria Cossu Rocca, Elena Verri, Daniela Cullurà, Franco Nolé & Franco Orsi. (2023) Image-Guided Ablations in Patients with Recurrent Renal Cell Carcinoma. Journal of Clinical Medicine 12:15, pages 4902.
Crossref
Crossref
Kyle Nolla, David J. Benjamin & David Cella. (2023) Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment. Nature Reviews Urology 20:7, pages 420-433.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Valentina Tateo, Elisa Tassinari, Andrea Marchetti, Matteo Rosellini, Raffaele De Luca, Matteo Santoni & Francesco Massari. (2023) Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunology, Immunotherapy 72:6, pages 1381-1394.
Crossref
Crossref
Matteo Santoni, Alessandro Rizzo, Jakub Kucharz, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, Fernando Sabino Marques Monteiro, Andrey Soares, Javier Molina-Cerrillo, Enrique Grande, Nicola Battelli & Francesco Massari. (2023) Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunology, Immunotherapy 72:6, pages 1365-1379.
Crossref
Crossref
Yu Fujiwara, Hirotaka Miyashita & Bobby C. Liaw. (2022) First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis. Cancer Immunology, Immunotherapy 72:6, pages 1355-1364.
Crossref
Crossref
Ava Safaroghli-Azar, Fatemeh Emadi, Jimma Lenjisa, Laychiluh Mekonnen & Shudong Wang. (2023) Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies. Drug Discovery Today 28:5, pages 103525.
Crossref
Crossref
Yuejun Luo, Yuxin Yao, Peng Wu, Xiaohui Zi, Nan Sun & Jie He. (2023) Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 183, pages 103922.
Crossref
Crossref
Alessandro Rizzo, Giacomo Nuvola, Gennaro Palmiotti, Selma Ahcene-Djaballah, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Maria Concetta Nigro, Elisa Tassinari, Sveva Macrini & Francesco Massari. (2023) Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis. Immunotherapy 15:2, pages 117-126.
Crossref
Crossref
Na Li, Zixuan Wan, Dongyan Lu, Ruilian Chen & Xiaowei Ye. (2023) Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review. Frontiers in Immunology 13.
Crossref
Crossref
Meriem Andrif, Hafsa Elmarrachi & Nabil Ismaili. (2023) Paradigm change in urological, gynaecological and breast cancer management: A new practice-changing data from ASCO 2022 annual meeting. Cancer Treatment and Research Communications 35, pages 100677.
Crossref
Crossref
Morgan Marriott, Brittany Post & Lipika Chablani. (2022) A Comparison of Cancer Vaccine Adjuvants in Clinical Trials. Cancer Treatment and Research Communications, pages 100667.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Matteo Santoni & Francesco Massari. (2022) Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer. Journal of Clinical Medicine 11:21, pages 6356.
Crossref
Crossref
Koji Iinuma, Koji Kameyama, Tomoki Taniguchi, Kei Kawada, Takashi Ishida, Kimiaki Takagi, Shingo Nagai, Torai Enomoto, Masayuki Tomioka, Makoto Kawase, Shinichi Takeuchi, Daiki Kato, Manabu Takai, Keita Nakane & Takuya Koie. (2022) Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study. Cancers 14:19, pages 4579.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Matteo Santoni & Francesco Massari. (2022) Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis. Immunotherapy 14:8, pages 617-625.
Crossref
Crossref
Xiao Zhou & Guangcheng Luo. (2022) A meta-analysis of the platelet-lymphocyte ratio: A notable prognostic factor in renal cell carcinoma. The International Journal of Biological Markers 37:2, pages 123-133.
Crossref
Crossref
Brendan Sieber, Julius Strauss, Zihai Li & Margaret E. Gatti-Mays. (2022) Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity. Frontiers in Oncology 12.
Crossref
Crossref
Dengdeng Pan, Dongliang Liu, Lichuan Liang, Tongyi Shen, Chenzhang Shi & Huanlong Qin. (2022) Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients. Frontiers in Oncology 12.
Crossref
Crossref
W. J. Mullally, F. J. Cooke, I. M. Crosbie, S. Kumar, V. E. Abernethy, E. J. Jordan, M. O’Connor, A. M. Horgan, R. Landers, J. Naidoo & P. M. Calvert. (2022) Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma. Frontiers in Immunology 13.
Crossref
Crossref
Stavroula A. Paschou, Michael Liontos, Evangelos Eleftherakis-Papaiakovou, Katerina Stefanaki, Christos Markellos, Konstantinos Koutsoukos, Flora Zagouri, Theodora Psaltopoulou & Meletios-Athanasios Dimopoulos. (2022) Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. Frontiers in Oncology 12.
Crossref
Crossref
Anna Gluba-Brzózka, Jacek Rysz, Janusz Ławiński & Beata Franczyk. (2022) Renal Cell Cancer and Obesity. International Journal of Molecular Sciences 23:6, pages 3404.
Crossref
Crossref
Long Meng, Jing Huang, Feng Qiu, Xuefeng Shan, Lin Chen, Shusen Sun, Yuwei Wang & Junqing Yang. (2022) Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions. Frontiers in Pharmacology 13.
Crossref
Crossref
Daniel M Geynisman, Ella X Du, Xiaoran Yang, Selvam R Sendhil, Viviana Del Tejo, Keith A Betts & Stephen Huo. (2022) Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. Future Oncology 18:10, pages 1219-1234.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Angela Dalia Ricci, Matteo Rosellini, Andrea Marchetti, Rodolfo Montironi, Andrea Ardizzoni & Francesco Massari. (2022) Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. European Urology Focus 8:2, pages 514-521.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Matteo Rosellini, Andrea Marchetti & Francesco Massari. (2022) Risk of toxicity with immunotherapy–tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. Future Oncology 18:5, pages 625-634.
Crossref
Crossref
Qian Chen, Qizhong Fu, Lin Pu, Xianfeng Liu & Ying Liu. (2022)
Effects of
HMGA2
gene silencing on cell cycle and apoptosis in the metastatic renal carcinoma cell line ACHN
. Journal of International Medical Research 50:2, pages 030006052210755.
Crossref
Crossref
Jee Soo Park, Myung Eun Lee, Won Sik Jang, Jongchan Kim, Se Mi Park & Won Sik Ham. (2022) Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers. Biomedicines 10:2, pages 321.
Crossref
Crossref
Rashida Orlova, Natalia Zhukova, Anna Malkova & Yehuda Shoenfeld. (2022) Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy. Cancer Treatment and Research Communications 31, pages 100529.
Crossref
Crossref
Wylie M. Masterson, Alexandria M. Brown, May A. Al Ameri & Anisha B. Patel. (2022) A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution. Cancer Treatment and Research Communications 30, pages 100506.
Crossref
Crossref
Oliver Pavlovic, Tvrtko Hudolin, Ivan Miskulin, Stela Bulimbasic, Marijana Coric, Josip Perkovic & Toni Zekulic. (2021) Immunohistochemical Expression of Wnt-4 Protein in Clear Cell Renal Carcinoma. Journal of Clinical Medicine 10:24, pages 5795.
Crossref
Crossref
Myung-Chul Kim, Zeng Jin, Ryan Kolb, Nicholas Borcherding, Jonathan Alexander Chatzkel, Sara Moscovita Falzarano & Weizhou Zhang. (2021) Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers 13:22, pages 5856.
Crossref
Crossref
Koji Iinuma, Torai Enomoto, Kei Kawada, Shota Fujimoto, Takashi Ishida, Kimiaki Takagi, Shingo Nagai, Hiroki Ito, Makoto Kawase, Chie Nakai, Kota Kawase, Daiki Kato, Manabu Takai, Keita Nakane, Koji Kameyama & Takuya Koie. (2021) Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. Journal of Clinical Medicine 10:22, pages 5325.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Matteo Santoni & Francesco Massari. (2021) Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution. Journal of Clinical Medicine 10:22, pages 5246.
Crossref
Crossref
Yann-Alexandre Vano, Sylvain Ladoire, Réza Elaidi, Slimane Dermeche, Jean-Christophe Eymard, Sabrina Falkowski, Marine Gross-Goupil, Gabriel Malouf, Bérangère Narciso, Christophe Sajous, Sophie Tartas, Eric Voog & Alain Ravaud. (2021) First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?. Cancers 13:21, pages 5548.
Crossref
Crossref
Haibin Wei, Jia Miao, Jianxin Cui, Wei Zheng, Xinpeng Chen, Qi Zhang, Feng Liu, Zujie Mao, Songlin Qiu & Dahong Zhang. (2021) The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database. Scientific Reports 11:1.
Crossref
Crossref
Francesco Massari, Alessandro Rizzo, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Andrea Ardizzoni & Matteo Santoni. (2021) Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. European Journal of Cancer 154, pages 120-127.
Crossref
Crossref
Bin Zheng, Zhihong Niu, Shubin Si, Guiting Zhao, Jianwei Wang, Zhongshun Yao, Fajuan Cheng & Wei He. (2021) Comprehensive analysis of new prognostic signature based on ferroptosis-related genes in clear cell renal cell carcinoma. Aging 13:15, pages 19789-19804.
Crossref
Crossref
Lichen Zhang, Deqiong Xie, Yonghua Lei, Aoli Na & Lei Zhu. (2021) Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma. Future Oncology 17:23, pages 3051-3060.
Crossref
Crossref
Omar Alhalabi, Elshad Hasanov, Nathaniel R. Wilson, John Araujo, Jianbo Wang, Matthew T. Campbell, Sangeeta Goswami, Amishi Y. Shah, Jianjun Gao, Pavlos Msaouel & Nizar M. Tannir. (2021)
Outcomes of patients with intermediate‐risk or poor‐risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The
MD
Anderson Cancer Center experience
. International Journal of Cancer 149:2, pages 387-393.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Filippo Gustavo Dall’Olio, Angela Dalia Ricci, Ilaria Maggio, Andrea Marchetti, Matteo Rosellini, Matteo Santoni, Andrea Ardizzoni & Francesco Massari. (2021) Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. Future Oncology 17:20, pages 2671-2681.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Giada Grilli, Alba Greco, Rodolfo Montironi, Andrea Ardizzoni & Francesco Massari. (2021) Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. Immunotherapy 13:9, pages 783-793.
Crossref
Crossref
Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Veronica Mollica & Francesco Massari. (2021) Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy 13:8, pages 685-692.
Crossref
Crossref
Ke Wu, Xinyi Zheng, Zhixian Yao, Zhong Zheng, Wenjie Huang, Xingyu Mu, Feng Sun, Zhihong Liu & Junhua Zheng. (2021) Accumulation of CD45RO+CD8+ T cells is a diagnostic and prognostic biomarker for clear cell renal cell carcinoma. Aging 13:10, pages 14304-14321.
Crossref
Crossref
Carmen Portenkirchner, Peter Kienle & Karoline Horisberger. (2021) Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. Pharmaceuticals 14:4, pages 367.
Crossref
Crossref
Maria Massucci, Veronica Mollica, Alessandro Rizzo, Laura Ventrella, Ilaria Maggio, Lisa Manuzzi, Lidia Gatto, Giovanni Brandi & Francesco Massari. (2021) Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. Medicines 8:1, pages 5.
Crossref
Crossref
Alessandro Rizzo & Giovanni Brandi. (2021) First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!”. Cancer Treatment and Research Communications 27, pages 100335.
Crossref
Crossref
Alessandro Rizzo & Giovanni Brandi. (2021) Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treatment and Research Communications 27, pages 100328.
Crossref
Crossref
Sascha D. Markowitsch, Patricia Schupp, Julia Lauckner, Olesya Vakhrusheva, Kimberly S. Slade, René Mager, Thomas Efferth, Axel Haferkamp & Eva Juengel. (2020) Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis. Cancers 12:11, pages 3150.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Alessia Cimadamore, Matteo Santoni, Marina Scarpelli, Francesca Giunchi, Liang Cheng, Antonio Lopez-Beltran, Michelangelo Fiorentino, Rodolfo Montironi & Francesco Massari. (2020) Is There a Role for Immunotherapy in Prostate Cancer?. Cells 9:9, pages 2051.
Crossref
Crossref